Haier Biotech announced that in the first half of 2026, it achieved operating income of 1,296 billion yuan, an increase of 8.45% year on year; net profit attributable to shareholders of listed companies was 147 million yuan, up 3.28% year on year; and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 138 million yuan, an increase of 11.39% year on year. Basic earnings per share were $0.47, up 4.44% year over year. R&D investment accounted for 13.31% of revenue, a year-on-year decrease of 0.08 percentage points. As of the end of the reporting period, the company's special securities account held 3.6541 million shares, accounting for 1.15% of the total share capital. There are no profit distribution plans for the reporting period.

Haier Biotech announced that in the first half of 2026, it achieved operating income of 1,296 billion yuan, an increase of 8.45% year on year; net profit attributable to shareholders of listed companies was 147 million yuan, up 3.28% year on year; and net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 138 million yuan, an increase of 11.39% year on year. Basic earnings per share were $0.47, up 4.44% year over year. R&D investment accounted for 13.31% of revenue, a year-on-year decrease of 0.08 percentage points. As of the end of the reporting period, the company's special securities account held 3.6541 million shares, accounting for 1.15% of the total share capital. There are no profit distribution plans for the reporting period.